about
Lost in Translation (LiT): IUPHAR Review 6Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studiesAntibody-drug conjugates as novel anti-cancer chemotherapeuticsGeneration of monoclonal antibodies against native viral proteins using antigen-expressing mammalian cells for mouse immunizationNovel approach to activity evaluation for release-active forms of anti-interferon-gamma antibodies based on enzyme-linked immunoassaySeizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody development in China.Use of Piezoelectric Immunosensors for Detection of Interferon-Gamma Interaction with Specific Antibodies in the Presence of Released-Active Forms of Antibodies to Interferon-GammaVNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicryEmerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.A tool kit for rapid cloning and expression of recombinant antibodies.Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.Peptide aptamers: development and applications.The origin of CDR H3 structural diversity.Therapeutic antibody engineering by high efficiency cell screening.A highly functional synthetic phage display library containing over 40 billion human antibody clones.An improved fast photochemical oxidation of proteins (FPOP) platform for protein therapeutics.Dissecting antibodies with regards to linear and conformational epitopes.Anti-Semaphorin 3A neutralization monoclonal antibody prevents sepsis development in lipopolysaccharide-treated mice.scFv from Antibody That Mimics gp43 Modulates the Cellular and Humoral Immune Responses during Experimental Paracoccidioidomycosis.Effects of an amyloid-beta 1-42 oligomers antibody screened from a phage display library in APP/PS1 transgenic mice.Evolution of phage display technology: from discovery to application.A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies.Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes.Research and development of therapeutic mAbs: An analysis based on pipeline projects.Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development.SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts.Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodiesDevelopment of an antigen microarray for high throughput monoclonal antibody selection.Monoclonal antibodies for the treatment of osteoporosis.Developing therapeutic antibodies for neurodegenerative disease.Proteins improving recombinant antibody production in mammalian cells.Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development.Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.Structural insights and biomedical potential of IgNAR scaffolds from sharks.Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.Single-domain antibodies for biomedical applications.A snapshot of biologic drug development: Challenges and opportunities.Overview on biotherapeutic proteins: impact on bioanalysis.
P2860
Q24289150-035C8305-4472-426D-B2AE-1AA1D5F563C7Q26781698-81DFD9BF-64BC-488C-A581-97746840995FQ26800175-242C4741-924E-476F-84B4-6985960E5D9DQ28119660-CCFB9EBA-270A-4696-95CB-5818B59C6039Q28538689-DF0BFE5B-2904-4B87-B812-E83B49793F12Q30387074-BD1FC063-1BDE-40BE-B5C9-C9083ABEF5D2Q30391107-C80759C2-716E-44DD-ACBC-9D433F210BD7Q33688370-A02D6318-73A9-46ED-AE8E-FB2665E0C623Q33838871-C2FB8C0C-A5FB-42E6-889C-BDE0A9F01252Q33970343-5948E819-5BB5-4F42-9F8C-D2C72C94607EQ34204024-58417787-60AD-4C50-AF9D-D033F2725C7CQ34471346-5A8075C5-599F-4ED0-8339-1749CDF68846Q35054394-345B89E9-70B7-4D0D-AF39-EAD887DAD6FAQ35056966-7835E36F-639C-47E9-A419-02C8689D0916Q35192223-7ADE0B6D-3411-4480-B9F2-452BD3102B90Q35528871-83A97569-24D6-4BAF-900E-F88A3246CCC8Q35588816-7BB3333E-DE73-4FF9-A081-5AEC3FB1356AQ35597952-0A5E8D4E-2869-43BE-9202-A447F8B9134BQ35668952-6D9F8709-A2E4-4C5C-96DC-E128DA9D4016Q35907101-83862AA2-BD66-4DA4-9877-DB31F3907AF0Q36183954-CF7C4DB3-FE66-4D94-8916-CD11469A8A07Q36213182-3AD102A8-90BB-4743-886A-13FD6EAF71C0Q36248059-9B70BBBF-F263-4C5A-B6A8-571177963B01Q36257660-677F8E27-7B7D-4E6E-926E-52A01DB75491Q37027607-A3F8122D-5A89-458D-975F-10C05B82C259Q37120976-85AC68BA-789B-4953-9FA5-0CF9D25D8BCDQ37271866-B3889A08-9364-4952-BBFB-F562ACE1C392Q37567087-56DDFA54-41ED-4D9C-839E-F2456E25A2E5Q37706541-9D9579C8-F158-45FD-BA61-389EBF2928DAQ38068600-F6E3DDBA-BE70-4B84-9CCC-A179BA3F86FCQ38095360-D125C043-C6AF-4F15-AE79-17B8180ADBC7Q38170315-512DF6DA-24B0-471C-A072-0FAA8910FCF1Q38236706-F1AE49DD-18A1-4BDD-B715-4A2F27062CACQ38286209-DBC9D7F0-7CA5-48CA-9F00-CB6AD354822FQ38293902-BD26AD42-DA49-4799-A58E-069CDAFF21B4Q38564877-B3CD1098-7CB7-4330-A0C9-0ABF61389B87Q38575679-6636EFE9-0F8C-4156-9896-6773A2FF4055Q38628712-840CC08E-F062-4163-8E2E-EEFCA15AC3FAQ38651271-E290D735-ACB1-44A1-9357-44D98B4DD245Q38663214-2567086F-6767-448B-98F5-9CABF8F92BF6
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Monoclonal antibody therapeutics: history and future.
@en
type
label
Monoclonal antibody therapeutics: history and future.
@en
prefLabel
Monoclonal antibody therapeutics: history and future.
@en
P2093
P1476
Monoclonal antibody therapeutics: history and future.
@en
P2093
Jacintha M Shenton
Lolke de Haan
Mary McFarlane
Nicholas A P S Buss
Simon J Henderson
P304
P356
10.1016/J.COPH.2012.08.001
P577
2012-08-21T00:00:00Z